Literature DB >> 9210989

Psychomotor agitation following gabapentin use in brain injury.

M K Childers1, D Holland.   

Abstract

Gabapentin, an anticonvulsant structurally related to gamma-aminobutyric acid (GABA) was recently reported to be effective in pain associated with reflex sympathetic dystrophy (RSD) and in pain associated with neuropathy. Yet, to our knowledge, the use of gabapentin for neuropathic pain in the presence of cognitive impairment has not been reported. In this report, we describe two patients (one with a traumatic brain injury, one with a putative acquired brain injury) who presented to a neurorehabilitation unit complaining of pain that was diagnosed as neurologically mediated. Within one week of receiving a daily 900 mg dose of gabapentin, both patients complained of heightened anxiety and restlessness. Correspondingly, each reported a diminution of psychological symptoms within 48 hours of gabapentin cessation. These two cases suggest that gabapentin may cause agitation in cognitive impaired patients. Physicians treating brain-injured patients and prescribing gabapentin for neuropathic pain may wish to closely monitor patients for similar signs of restlessness or anxiety.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210989

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  3 in total

1.  Using gabapentin to treat neuropathic pain.

Authors:  H Hays; M A Woodroffe
Journal:  Can Fam Physician       Date:  1999-09       Impact factor: 3.275

Review 2.  Adverse reactions to new anticonvulsant drugs.

Authors:  I C Wong; S D Lhatoo
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 3.  Systematic review of the literature on pain in patients with polytrauma including traumatic brain injury.

Authors:  Steven K Dobscha; Michael E Clark; Benjamin J Morasco; Michele Freeman; Rose Campbell; Mark Helfand
Journal:  Pain Med       Date:  2009-10       Impact factor: 3.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.